Owen McCarty/LinkedIn
May 17, 2026, 11:04
Owen McCarty: Few Insights and Implications from Recent Clinical Trials of FXI Inhibitors
Owen McCarty, Professor and Chair at Oregon Health and Science University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Advances in Therapy, adding:
”We summarized a few insights and implications from recent clinical trials of coagulation FXI inhibitors.”
Title: Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials
Authors: Rosemary B. Falama, Lisa R. Matsumoto, Marie E. Piatski, Lukas Seifer, Aditya Malhotra, Owen J. T. McCarty, Joseph J. Shatzel
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 10:05Ralf Ludwig: When a Promising Biomarker Falls Short
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation